Home > Analyse
Actualite financiere : Actualite bourse

Novo Nordisk: positive results on diabetes pen Xultophy.

(CercleFinance.com) - A phase 3b clinical trial has showed that Novo Nordisk's Xultophy is a better option to manage diabetes compared to multiple daily injections of insulin.

In the trial including 506 adults living with type-2 diabetes assessing their physical health, mental health and a number of diabetes-specific factors, Xultophy was reported by participants as "a better option" than basal-bolus insulin therapy.

In addition, more people preferred to stay on Xultophy, a once-daily single injection in one pen, rather on basal-bolus therapy (84.5% versus 68.1%), the results showed.

Novo Nordisk has presented these results today at the International Diabetes Federation Congress in Abu Dhabi.

Copyright (c) 2017 CercleFinance.com. All rights reserved.